Latest Profit Guidance News

SKS Technologies Group is set to surpass its February profit forecast with an unaudited before-tax profit of $39.3 million, driven by operational discipline and scalable growth.

Briscoe Group reports a third consecutive quarter of sales growth with second quarter revenue edging up 0.25% to $193.4 million, while online sales and sporting goods categories drive resilience despite headwinds in homewares.

Raiz Invest reported robust Q4 FY26 growth with active customers climbing 6.7% and funds under management hitting $2.32 billion, while confirming FY26 profitability guidance.

MaxiPARTS upgrades FY26 operating profit guidance to $14.2 million, driven by strong cost control and a $9 million inventory reduction, while bolstering its executive team with key appointments.

Tourism Holdings Limited has upgraded its FY26 underlying net profit after tax to around $46 million, beating earlier guidance. The company reports strong vehicle sales in New Zealand and robust late bookings, particularly in North America, while net debt ended lower than expected.

Kingfish Limited outperformed the S&P/NZX50G with an 8.7% gross portfolio return in Q2 2026, driven by strong results from Fisher & Paykel Healthcare, Vista Group, and Infratil, while a2 Milk faced supply chain and regulatory challenges.

Skellerup has raised its FY26 net profit after tax forecast to $64-$65 million, driven by robust demand in the US and New Zealand markets, improved supply chain conditions, and favourable currency and tariff impacts.

Ingenia Communities is in discussions with Peet Limited and potential capital partners to extend its land lease portfolio beyond its current five-year plan, aiming to boost scale and financial flexibility.

Brambles Limited has lodged an appeal against a Federal Court judgment in a class action involving shareholders from 2016-2017. The company maintains insurance coverage and promises ongoing market updates.

Autosports Group reports a 22% jump in order write driven by battery electric vehicles, with FY26 profit forecast raised to $51-54 million.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.